Imported drugs:
□ Alecensa (alectinib) - new indication - marketed by Roche Registration GmbH
□ Awiqli (insulin icodec) - marketed by Novo Nordisk A/S
□ Budesonide, glycopyrronium bromide and formoterol fumarate inhalation aerosol - marketed by AstraZeneca AB
□ DOPTELET (avatrombopag maleate) - new indication - marketed by AkaRx Inc.
□ Esperoct (turoctocog alfa pegol) - marketed by Novo Nordisk A/S
□ Glucagon nasal powder - marketed by Amphastar Pharmaceuticals, Inc.
□ Icosapent ethyl soft capsules - marketed by Amarin Pharmaceuticals Ireland Ltd.
□ Jakavi (ruxolitinib) - new indication - marketed by Novartis Pharma Schweiz AG
□ Keytruda (pembrolizumab) - new indication - marketed by Merck Sharp & Dohme LLC
□ Methylthioninium chloride enteric-coated sustained-release tablets - marketed by Alfasigma S.p.A.
□ ORKEDIA (eocalcet) - marketed by Kyowa Kirin Co., Ltd.
□ Ozempic (semaglutide) - new indication - marketed by Novo Nordisk Pharma AG
□ REXULTI (brexpiprazole) - marketed by Otsuka Pharmaceutical Co.，Ltd.
□ Tabrecta (capmatinib) - marketed by Novartis Pharma Schweiz AG
□ TAGRISSO (osimertinib mesylate) - new indication - marketed by AstraZeneca AB
□ Tarlige (mirogabalin besilate) - marketed by DAIICHI SANKYO CO., LTD.
□ TECVAYLI (teclistamab) - marketed by Janssen-Cilag International NV
□ XPOVIO (selinexor) - new indication - marketed by Karyopharm Therapeutics Inc.
□ XTANDI (enzalutamide) - new indication - marketed by Astellas Pharma Europe B.V.
Domestic drugs:
□ 安洛晴-An Luo Qing (envonalkib citrate) - marketed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
□ 百斯锐明-Bai Si Rui Ming (ropeginterferon alfa-2b) – marketed by PharmaEssentia Corporation
□ 百泽安-Bai ze An (tislelizumab) – new indication - marketed by BeiGene Ltd.
□ 倍长平-Bei Chang Ping (cofrogliptin) - marketed by Haisco Pharmaceutical Group Co., Ltd.
□ 贝塔宁-BETAGRIN (bevifibatide citrate) - marketed by Bio-Thera Solutions Inc.
□ Brivaracetam tablets - marketed by Qingfeng Pharmaceutical Group Co. Ltd.
□ Calcipotriol scalp solution - marketed by Sinomune Pharmaceutical Co., Ltd.
□ Calcitriol injection - marketed by Chengdu Gowell Biopharmaceutical Co., Ltd.
□ Carbidopa and levodopa sustained-release tablets - marketed by SJZ No.4 Pharmaceutical Co., Ltd.
□ Cetirizine hydrochloride injection - marketed by Shandong Cosci Med-tech Co., Ltd.
□ 恩立妥-En Li Tuo (cetuximab beta) – marketed by Taizhou Mabtech Pharmaceutical Co. Ltd.
□ 恩舒幸-En Shu Xing (enlonstobart) - marketed by CSPC Megalith Biopharmaceutial Co., Ltd.
□ Estradiol valerate tablets - marketed by Zhejiang Xianju Pharmaceutical Co., Ltd.
□ Fexofenadine hydrochloride for suspension - marketed by Jumpcan Pharmaceutical Group Co., Ltd.
□ 高瑞哲-Gao Rui Zhe (golidocitinib) - marketed by Dizal Pharmaceutical Co.,Ltd.
□ 克瑞毕-Ke Ru Bi (zamerovimab and mazorelvimab) - marketed by Synermore Biologics (Suzhou) Co., Ltd.
□ Levofloxacin oral solution - marketed by Hubei Jinluo Silk Cloth Co., Ltd.
□ Metformin hydrochloride and empagliflozin tablets (VI) - marketed by Qilu Pharmaceutical Co., Ltd.
□ Naltrexone hydrochloride implants - marketed by SciencienCare Pharmaceutical Technology Co.,Ltd.
□ Olmesartan medoxomil orally disintegrating tablets - marketed by ApicHope Pharmaceutical Co., Ltd.
□ Oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets - marketed by Shandong Luye Pharmaceutical Co., Ltd.
□ Palbociclib tablets - marketed by CSPC Ouyi Pharmaceutical Co., Ltd.
□ Perfluoropropane-albumin microspheres for injection - marketed by Xiamen Lizhuo Pharmaceutical Co., Ltd.
□ Phloroglucinol orally disintegrating tablets - marketed by Renhe Yikang Group Co., Ltd.
□ Pregabalin orally disintegrating tablets - marketed by DiQi Pharmaceuticals Co.,Ltd.
□ Progesterone injection (II) - marketed by Changchun GeneScience Pharmaceutical Co., Ltd.
□ Rivastigmine bitartrate oral solution - marketed by Shandong Loncom Pharmaceutical Co., Ltd.
□ Rotigotine microspheres for injection - marketed by Luye Jiaao (Shijiazhuang) Pharmaceutical Co., Ltd.
□ 瑞沁-Rui Qin (henagliflozin proline) – new indication - marketed by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
□ Salmeterol xinafoate and fluticasone propionate powder for inhalation - marketed by Joincare Pharmaceutical Group Industry Co., Ltd.
□ 圣瑞沙-Sheng Rui Sha (rilertinib mesylate) - marketed by Nanjing Sanhome Pharmaceutical Co., Ltd.
□ Sodium dihydrogen phosphate and disodium hydrogen phosphate granules - marketed by Harvest(Hunan) Pharmaceuticals Co.,Ltd.
□ Tafamidis meglumine soft capsules - marketed by Qilu Pharmaceutical Co., Ltd.
□ Technetium [⁹⁹ᵐTc] tetrofosmin injection - marketed by Nanjing JYAMS Electronic Research & Development Co., Ltd.
□ Telmisartan and amlodipine tablets - marketed by Jiangxi Shimei Pharmaceutical Co., Ltd.
□ Ticagrelor dispersible tablets - marketed by Honghe Pharmaceutical Co., Ltd.
□ 拓益-Tuo Yi (toripalimab) – new indication - marketed by Shanghai Junshi Biosciences Co., Ltd.
□ Valganciclovir hydrochloride tablets - marketed by Shanghai Zhongxi Sunve Pharmaceutical Co.,Ltd.
□ 信立汀-Xin Li Ting (fultagliptin benzoate) - marketed by Shenzhen Salubris Pharmaceuticals Co., Ltd.
(Source: BaiPharm)
